Canadian Acquisitions: QLT Inc. Fits the Trend
Research - It seems QLT Inc. may be on the block after a press release on Wednesday evening indicated the company has engaged Credit Suisse as a … Continue Reading
Read NowResearch
No News for QLTI, Yet the Stock is Going
Research - Note: This article was sent to PropThink Premium members during the afternoon of November 20, 2013. Also see our follow-up commentary here. In morning trading, … Continue Reading
Premium: Read Now
It’s a Bit Early to Go Big, but AcelRx Has a Pivotal 2014
Research - We’ve watched AcelRx Pharmaceuticals (ACRX) for some time in 2013 as the stock has pulled back meaningfully, falling from a high of over $13 to … Continue Reading
Premium: Read Now
This Antibiotic Play May Be the Trius of 2014
Research - 2013 has been a year of change in the landscape for publicly traded antibiotic developers, driven by Cubist Pharmaceuticals’ (CBST) high-profile acquisitions of competitors Trius … Continue Reading
Read Now
The Long Case for Zogenix
Research - Zogenix (ZGNX) expects to net $56 million from a secondary offering revealed on November 4, $64.4 million with full exercise of the underwriter’s over-allotment option. … Continue Reading
Read Now
Why Doctors, Dialysis Providers, and Investors are Excited about Zerenex
Research - When investing in development-stage biotech companies, evidence of success is everything. Therefore, investors should always start with the question: Is the company’s product candidate a … Continue Reading
Read NowPropThink’s Biotech Roundup: A Few Stories from the Week
Recap - Endo Health Solutions (ENDP) announced plans on Tuesday to purchase Paladin Labs (PLB.TO), a Canadian specialty pharmaceutical manufacturer, for $1.5 billion. ENDP fell significantly in 2012 on … Continue Reading
Read Now